Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Accured Expenses: 2023-2024

Historic Change in Accured Expenses for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $5.5 million.

  • CG Oncology's Change in Accured Expenses fell 180.39% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 112.55%. This contributed to the annual value of $5.5 million for FY2024, which is 32.17% up from last year.
  • Per CG Oncology's latest filing, its Change in Accured Expenses stood at $5.5 million for FY2024, which was up 32.17% from $4.1 million recorded in FY2023.
  • CG Oncology's Change in Accured Expenses' 5-year high stood at $5.5 million during FY2024, with a 5-year trough of $4.1 million in FY2023.
  • For the 2-year period, CG Oncology's Change in Accured Expenses averaged around $4.8 million, with its median value being $4.8 million (2023).
  • Data for CG Oncology's Change in Accured Expenses shows a peak YoY spiked of 32.17% (in 2024) over the last 5 years.
  • CG Oncology's Change in Accured Expenses (Yearly) stood at $4.1 million in 2023, then soared by 32.17% to $5.5 million in 2024.